Eyenovia provides clinical, scientific update on FDA-approved products Mydcombi and clobetasol propionate ophthalmic suspension
The company announced results from a Phase IV study of tropicamide and phenylephrine hydrochloride ophthalmic spray 1%/2.5% (Mydcombi) designed to characterize the efficacy and duration of the lowest deliverable dose.